

4 July 2016

MMJ PHYTOTECH APPOINTS CHIEF FINANCIAL OFFICER

MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to advise that it has further strengthened its senior management personnel with the appointment of Richard Jarvis as Chief Financial Officer.

Mr Jarvis will be responsible for all finance and accounting aspects of the Group, including the management of financial risk and leading financial strategy and planning. He will provide valuable financial support and guidance through the complexity of a multi-jurisdictional business model, as the Company continues to advance its vertically integrated “Farm to Pharma” strategy.

Mr Jarvis is a Chartered Certified Accountant with twenty years experience in professional accountancy and finance leadership roles. The first ten years of his career he spent working in a business advisory capacity both in the UK and Australia, providing professional accounting services to a diverse client base. For the last ten years he has held senior managerial roles, including acting as Chief Financial Officer for a number of publicly-listed companies with international operations, listed on the Australian Stock Exchange and/or the AIM market of the London Stock Exchange.

MMJ PhytoTech Limited’s Managing Director, Andreas Gedeon, commented: “Mr Jarvis is a solutions orientated finance executive who has worked across multiple jurisdictions and has accumulated extensive experience in a listed company environment. We are very pleased with his appointment and look forward to his contribution to the business as we move forward developing our position as an industry leader in the emerging global markets of medical cannabis and cannabis based pharmaceuticals.”

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yisum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.